Cargando…
Sarcopenia Predicts Cancer Mortality in Male but Not in Female Patients Undergoing Surgery for Cholangiocellular Carcinoma
SIMPLE SUMMARY: Cholangiocellular adenocarcinoma is the second most common primary liver tumor. If resectable, this is the therapeutic method of choice. Unfortunately, there are insufficient prognostic markers to determine which patients benefit most from surgery and which do not. The general condit...
Autores principales: | Jördens, Markus Sebastian, Heinrichs, Lisa, Loosen, Sven H., Wittig, Linda, Keitel, Verena, Schöler, David, Schulze-Hagen, Maximilian, Loberg, Christina, Antoch, Gerald, Knoefel, Wolfram Trudo, Luedde, Tom, Fluegen, Georg, Roderburg, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582463/ https://www.ncbi.nlm.nih.gov/pubmed/34771524 http://dx.doi.org/10.3390/cancers13215359 |
Ejemplares similares
-
Bone Mineral Density Is a Predictor of Mortality in Female Patients with Cholangiocellular Carcinoma Undergoing Palliative Treatment
por: Jördens, Markus S., et al.
Publicado: (2022) -
Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment
por: Jördens, Markus S., et al.
Publicado: (2021) -
Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies
por: Loosen, Sven H., et al.
Publicado: (2023) -
Update on Locoregional Therapies for Cholangiocellular Carcinoma
por: Morawitz, Janna, et al.
Publicado: (2023) -
Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
por: Loosen, Sven H., et al.
Publicado: (2021)